Top Five Prostate Cancer Imaging Content in 2025

We take a look back at the most well-viewed prostate cancer (PCa) imaging content from 2025 with topics ranging from the prognostic value of baseline PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) and the potential of abbreviated MRI for imaging of clinically significant prostate cancer (csPCa) to a meta-analysis examining the use of PSMA PET for detecting PCa recurrence and metastasis. Review the slideshow below to see highlighted PCa imaging content from the past year.